The safety profile of givinostat in the current study was consistent with previous studies in other diseases, including JAK2 positive chronic myeloproliferative neoplasms such as polycythemia vera (36–38), with adverse events being predominantly mild to moderate in severity and more frequent at the higher dose. Here, JAK2 is linked to acquired polycythemia vera.